GRCL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 vas. 2024 @ 23:00):

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China...

Stats
Šios dienos apimtis	6.37M
Vidutinė apimtis	1.46M
Rinkos kapitalizacija	989.87M
EPS	CNY-0.810 ( Q3 \| 2023-09-30 )
Kita pelno data	( CNY0 ) 2024-08-12
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-10.57 (Sector) 42.63 (Industry) 24.32
ATR14	CNY0.215 (2.10%)

AADI -3.55%

ABCL -5.26%

ABCM 0.04%

ABEO -1.31%

ABIO -1.53%

ABOS -5.30%

ABSI -14.32%

ABUS -2.55%

ABVX -0.22%

ACAD -0.47%

ACER -17.95%

ACET -2.22%

ACGN 1.29%

ACHL 0.23%

ACHV 1.63%

ACIU -4.23%

ACLX -1.21%

ACRV -5.10%

ACST 0.62%

ACXP -0.42%

ADAG -5.64%

ADAP -7.23%

ADGI 0.87%

ADIL -2.29%

ADMA -1.79%

ADPT 0.32%

ADTX -7.69%

ADVM -3.94%

ADXN -6.11%

AEON 11.51%

AEZS -5.44%

AFMD -5.07%

AGEN -7.50%

AGIO -3.45%

AGLE 6.66%

AGTC 0.00%

AIKI 0.85%

AIMDW 53.45%

AKBA -1.87%

AKRO -4.46%

AKTX -6.33%

AKUS 0.00%

ALBO 0.00%

ALDX -1.34%

ALEC -2.35%

ALGS -5.76%

ALKS 2.08%

ALLK 0.86%

ALLO -2.13%

ALLR -3.01%

ALNA 3.16%

ALNY -1.93%

ALPN 0.00%

ALPX 0.00%

ALRN -0.31%

ALT -3.11%

ALVR -4.43%

ALXN 0.00%

ALXO -8.32%

ALZN -12.01%

AMRN -2.58%

AMTI -3.13%

ANAB -1.64%

ANEB -5.58%

ANGN 0.00%

ANIX -0.38%

ANL 0.61%

ANNX -4.63%

ANPC -3.15%

APGE -5.23%

APGN 8.48%

APGNW 30.65%

APLM -4.73%

APLS -3.98%

APLT -4.36%

APM 1.33%

APOP 0.38%

APRE 2.44%

APTO -3.96%

APTX 3.17%

APVO -20.53%

ARAV -13.39%

ARCT -9.26%

ARDS 20.48%

ARDX -0.94%

ARGX -2.25%

ARNA 0.00%

ARPO -0.90%

ARQT -7.76%

ARTL -0.38%

ARTLW 9.80%

ARVN -2.84%

ARWR -2.86%

ASLN -12.17%

ASMB -1.49%

ASND -2.39%

ATAI -2.19%

ATHA 2.36%

ATHE -1.61%

ATHX -33.50%

ATNF 15.09%

ATOS -4.17%

ATRA -16.93%

ATXI -1.66%

ATXS -3.50%

AUPH -1.95%

AURA 0.96%

AUTL -4.22%

AVBP -1.02%

AVEO 0.00%

AVIR -2.22%

AVRO 2.10%

AVTE -93.30%

AVTX 4.08%

AVXL -1.06%

AXLA 0.00%

AXSM 3.22%

AYLA 0.00%

AZRX 2.07%

BBI 2.17%

BBIO -2.26%

BCAB -1.89%

BCDA -2.05%

BCDAW -33.33%

BCEL -1.32%

BCLI -8.47%

BCRX 1.13%

BCTX 4.96%

BCTXW 0.00%

BCYC -4.33%

BDRX 1.89%

BDTX -8.38%

BEAM -3.38%

BFRA -2.91%

BGNE -1.97%

BIOR -10.12%

BIVI 0.41%

BLCM -6.68%

BLI -5.88%

BLPH -0.79%

BLRX -3.79%

BLTE -0.72%

BLU 0.03%

BLUE -0.77%

BMEA -9.75%

BMRN 1.81%

BNOX 1.64%

BNTC 2.46%

BNTX -3.95%

BOLD -5.95%

BOLT -0.82%

BPMC -1.59%

BPTH 10.65%

BPTS -13.47%

BRNS -6.63%

BRTX 20.00%

BTAI -2.92%

BTTX -7.50%

BTX 0.05%

BVXV 0.74%

BXRX 7.39%

BYSI 6.06%

CABA -12.20%

CADL -0.96%

CALA 60.00%

CALC -1.62%

CALT 0.03%

CAPR -4.06%

CARA -27.26%

CARM -9.65%

CASI -8.04%

CATB -6.97%

CBAY 0.03%

CBIO -2.65%

CBLI -7.31%

CBUS 3.07%

CCCC -5.48%

CCXI 0.00%

CDAK 0.00%

CDIO -1.51%

CDIOW -23.08%

CDMO 5.72%

CDMOP 0.04%

CDT -6.11%

CDTTW -47.71%

CDTX -6.32%

CDXC -0.67%

CDXS -2.30%

CELC -2.79%

CELU -2.19%

CELUW -9.52%

CERC -1.68%

CERE -0.16%

CERO -7.87%

CEROW -44.78%

CFRX -27.95%

CGEM 0.74%

CGEN -5.31%

CGON -2.68%

CGTX 0.92%

CHMA -6.00%

CHRS -2.96%

CINC 0.00%

CING -1.09%

CINGW -48.24%

CKPT -4.25%

CLBS -16.75%

CLDX 0.69%

CLGN 1.19%

CLLS -4.89%

CLNN -2.48%

CLNNW -41.25%

CLRB -9.94%

CLSD -0.84%

CLSN -0.68%

CLVS 0.00%

CMMB -24.79%

CMND 1.83%

CMPI 0.00%

CMPX 5.41%

CMRA 0.40%

CMRAW 33.33%

CMRX 1.44%

CNCE 0.00%

CNSP 3.94%

CNST 0.00%

CNTA -6.39%

CNTB 3.13%

CNTX -1.02%

COCP -0.16%

COEPW -0.66%

COGT 4.45%

CORT -1.31%

COYA -6.11%

CPRX -0.40%

CRBP -11.76%

CRBU -2.23%

CRDF -1.11%

CRGX -4.78%

CRIS 1.11%

CRNX -1.37%

CRSP -2.79%

CRTX 2.63%

CRVO -1.89%

CRVS -5.39%

CSBR 1.19%

CTCX -8.04%

CTIC 0.06%

CTMX -0.72%

CTNM 0.00%

CTXR -1.50%

CUE -1.47%

CVAC -5.18%

CVKD 3.18%

CWBR -2.55%

CYAD -12.96%

CYCC -3.55%

CYCCP -1.79%

CYCN 6.00%

CYT -2.27%

CYTK -2.13%

CYTO 2.48%

DARE -3.31%

DAWN -4.60%

DBTX -0.81%

DBVT 1.01%

DFFN 10.28%

DICE 0.06%

DMAC -0.42%

DNLI -1.21%

DNTH -2.85%

DOMH 1.99%

DRMA 0.00%

DRMAW 0.00%

DRNA 0.00%

DRTS -1.32%

DRTSW 1.01%

DRUG 0.00%

DSGN 2.97%

DTIL -2.07%

DYAI -5.29%

EARS -1.77%

EDIT 0.20%

EDSA 1.04%

EFTR -3.13%

EFTRW -0.26%

EIGR 0.00%

ELAB 1.44%

ELDN -6.93%

ELEV -7.89%

ELOX -12.50%

ELTX -2.33%

ELVN -0.65%

ELYM -13.05%

ENGN -3.89%

ENGNW -7.06%

ENLV -3.47%

ENOB 1.79%

ENSC -0.55%

ENTA -6.00%

ENTO -2.80%

ENTX 0.00%

ENVB -4.64%

EPIX -8.75%

EPRX -0.19%

EPZM 0.00%

EQ 0.50%

EQRX -2.09%

EQRXW 0.00%

ERAS -7.83%

ERNA 2.60%

ERYP 1.30%

ESLA -6.38%

ESLAW -9.25%

ETNB 1.03%

ETON -5.90%

ETTX 0.00%

EVAX -19.54%

EVGN -2.14%

EVLO 50.00%

EWTX -0.80%

EXAI 1.19%

EXEL 0.18%

EYEG -0.43%

EYEN 1.57%

EYPT -3.94%

FATE -1.11%

FBIO 1.60%

FBIOP -1.05%

FBLG -5.34%

FBRX -7.46%

FDMT 0.72%

FENC 0.74%

FGEN -5.36%

FHTX 9.52%

FIXX 0.77%

FMTX 0.00%

FNCH -6.25%

FOLD -0.99%

FREQ 4.76%

FRLN 0.15%

FRTX -0.54%

FSTX 0.00%

FTRE 0.38%

FULC -6.04%

FUSN 0.00%

FWBI 4.59%

FWP 0.00%

GALT -4.58%

GANX 6.45%

GBIO 6.57%

GBT 0.01%

GDTC 2.16%

GERN -4.11%

GHRS 3.42%

GLMD -6.66%

GLPG 1.18%

GLSI 18.16%

GLTO -4.90%

GLUE -4.18%

GLYC -9.70%

GMAB -1.57%

GMDA 0.00%

GMTX 0.00%

GNCA -85.71%

GNFT 0.14%

GNLX 1.27%

GNPX 1.84%

GNTA -0.60%

GOSS 0.02%

GOVX -7.50%

GOVXW -24.72%

GPCR 0.85%

GRAY -10.80%

GRCL 0.05%

GRNA -0.03%

GRNAW 8.91%

GRPH -2.75%

GRTS -2.71%

GRTX -4.26%

GTHX -3.96%

GUTS -3.90%

GXGXW 41.67%

GYRE 4.44%

HALO 0.32%

HARP 0.09%

HCWB -9.73%

HEPA -6.36%

HGEN -84.62%

HILS 5.66%

HLVX 1.33%

HOOK -4.04%

HOTH -3.73%

HOWL 3.99%

HRMY 1.10%

HRTX -10.42%

HSTO 62.16%

HUMA -12.20%

HUMAW -5.97%

IBRX -2.18%

ICCC 2.84%

ICPT 0.21%

ICU 1.30%

ICUCW -10.39%

ICVX -0.91%

IDRA -23.04%

IDYA -1.44%

IFRX -3.21%

IGMS 0.41%

IKNA -0.57%

IKT 8.90%

IMAB -1.09%

IMCR -3.82%

IMGN 0.02%

IMGO 0.00%

IMMP -0.74%

IMMX -0.49%

IMNM -11.86%

IMNN -1.80%

IMPL -27.27%

IMRA 15.96%

IMRN -2.78%

IMRX 1.66%

IMTX -0.08%

IMTXW -2.70%

IMUX -4.20%

IMV 0.00%

IMVT 3.08%

INAB -8.26%

INBX -9.62%

INCY 0.93%

INDP 7.98%

INFI -52.38%

INKT -1.05%

INM -2.58%

INMB -2.47%

INO -1.65%

INSM 1.22%

INTS -5.63%

INVA 1.57%

INZY -2.95%

IOBT -6.11%

IONS 0.27%

IOVA -0.98%

IPA 0.48%

IPHA -10.64%

IPSC 0.64%

IRON -3.05%

ISEE 0.38%

ITOS -6.04%

ITRM -1.74%

IVA -10.10%

IVVD -6.96%

JAGX -6.67%

JANX -4.57%

JAZZ 1.43%

JNCE 0.00%

JSPR -2.80%

JSPRW 2.33%

JUNS 0.00%

JUNSW 0%

KA 4.11%

KALV -2.07%

KDNY 0.22%

KMPH -0.34%

KNSA -1.28%

KNTE -0.38%

KOD -4.27%

KPRX -21.08%

KPTI 1.69%

KRBP 4.17%

KRON -3.70%

KROS -9.68%

KRRO -16.54%

KRTX 0.03%

KRYS -0.04%

KTRA -2.35%

KTTA -2.85%

KTTAW 8.62%

KURA -0.62%

KYMR -4.42%

KYTX -17.21%

KZIA -1.29%

KZR -2.71%

LABP 0.57%

LBPH 1.67%

LBPS 0.00%

LBPSW 14.81%

LEGN -2.24%

LENZ -0.54%

LEXX -5.18%

LEXXW -9.42%

LGND 0.72%

LGNDV 0.00%

LGVN -24.76%

LIAN 0.00%

LIFE 2.70%

LIPO -1.23%

LIXT 0.40%

LIXTW 27.74%

LJPC -0.32%

LMNL 0.12%

LOGC 2.76%

LPCN 12.64%

LPTX -1.90%

LQDA 3.01%

LRMR -14.91%

LSTA -4.97%

LTRN -8.57%

LUMO -2.95%

LVTX -9.52%

LXEO -6.50%

LXRX -5.49%

LYEL -8.05%

LYRA -8.37%

MACK 0.00%

MBIO 476.92%

MBRX -4.83%

MCRB -5.28%

MDGL -0.31%

MDNA -13.16%

MDWD 1.00%

MDXG 0.59%

MEIP 1.41%

MESO -0.55%

MGNX -4.03%

MGTA -7.74%

MGTX -2.23%

MGX -24.14%

MIRM 27.31%

MIRO 0.59%

MIST -1.42%

MITO 0.00%

MLEC -4.55%

MLECW 9.20%

MLND -5.36%

MLTX -2.99%

MLYS -3.02%

MNKD -1.04%

MNMD -3.36%

MNOV 0.00%

MNPR -8.51%

MOLN 8.81%

MOR 0.88%

MORF -1.25%

MREO 0.00%

MRKR 16.59%

MRNA -1.52%

MRNS -1.02%

MRSN -1.45%

MRTX -0.17%

MRUS -1.38%

MRVI -3.99%

MTCR -1.29%

MTEM 1.54%

MTP -18.50%

MURA 2.17%

MYMD 4.19%

NAMS -7.03%

NAMSW -7.61%

NAUT 0.00%

NBRV 0.71%

NBSE -1.56%

NBTX 4.77%

NCNA -1.64%

NERV 8.96%

NEXI 0.00%

NGM -1.28%

NGNE -6.08%

NKGN -4.44%

NKGNW 39.76%

NKTR 0.00%

NKTX -5.66%

NLSP 30.09%

NLSPW -16.67%

NMRA -4.09%

NMTR -42.97%

NOVN -24.84%

NRBO 0.45%

NRIX 0.72%

NRSN -3.82%

NRSNW 6.50%

NRXP 0.99%

NRXPW -15.65%

NRXS -6.06%

NTBL 13.82%

NTEC -12.45%

NTHI 0%

NTLA 0.08%

NTRBW -6.25%

NUVL -0.77%

NVAX -2.43%

NVCT 1.18%

NVIV -34.28%

NXTC -10.63%

NYMX -0.05%

OABI 0.95%

OABIW 13.46%

OBIO 0.88%

OBSV 0.00%

OCEA 10.64%

OCGN -5.63%

OCS -1.09%

OCUL -4.35%

OCUP 1.82%

ODT -4.27%

OKYO 0.00%

OLMA -3.96%

OMER -0.49%

OMGA -8.37%

ONCO 12.54%

ONCR -3.08%

ONCS 31.87%

ONCT -0.12%

ONCY -0.98%

ONTX -0.47%

ONVO 0.62%

OPNT 0.00%

OPT -5.51%

ORGS -1.72%

ORIC -0.67%

ORMP -0.44%

ORPH 0.00%

ORTX 0.30%

OSMT -1.77%

OTIC -92.64%

OTLK -1.43%

OVID -76.00%

OYST 0.00%

PALI 0.86%

PASG -3.81%

PBLA 9.76%

PBM -0.02%

PBYI 2.89%

PCSA 5.71%

PCVX -1.45%

PDSB -4.13%

PEPG 0.70%

PGEN 0.00%

PHAR 2.17%

PHAS 0.00%

PHAT 3.08%

PHIO 4.14%

PHIOW 36.47%

PHVS -0.53%

PHXM -5.20%

PIRS -5.64%

PKBO 0.00%

PKBOW 999 900.00%

PLRX -5.08%

PLUR 0.00%

PMN -5.59%

PMVP -1.20%

PNT 0.16%

PPBT -11.48%

PRAX -6.21%

PRDS 0.93%

PRLD 0.77%

PROG -3.47%

PROK 6.96%

PRQR -3.41%

PRTA -0.20%

PRTC -0.72%

PRTG -1.96%

PRTK 1.83%

PRVB 0.00%

PSTI -2.91%

PSTV 0.00%

PSTX 1.81%

PTCT -1.14%

PTE -0.82%

PTGX -2.76%

PTIXW 2.50%

PULM 3.72%

PXMD -1.92%

PYPD -0.36%

PYXS -3.43%

QLGN -11.72%

QNCX 0.00%

QNRX -10.97%

QSI -2.92%

QSIAW 0.00%

QTTB 3.82%

QURE -4.09%

RAIN -1.63%

RANI -5.46%

RAPT -0.30%

RARE 1.92%

RCKT -3.02%

REGN 0.85%

RENB -3.05%

REPL -6.63%

RETA 0.02%

REUN -0.89%

REVB 1.36%

REVBU 3.46%

REVBW 25.20%

RGLS -1.66%

RGNX -6.20%

RIGL -2.79%

RLAY -3.01%

RLMD -0.33%

RLYB -6.15%

RNA -0.10%

RNAC -14.55%

RNAZ -5.83%

RNXT 14.41%

ROIV 0.28%

ROIVW 4.56%

RPHM -0.60%

RPRX -1.15%

RPTX 0.00%

RUBY 2.70%

RVLP -32.05%

RVMD -3.94%

RVMDW -23.93%

RVNC -0.71%

RVPH -0.68%

RVPHW 11.54%

RXDX 0.09%

RXRX 1.19%

RYTM -3.76%

RYZB 0.02%

RZLT -2.53%

SABS 3.17%

SABSW -32.14%

SAGE -6.08%

SANA -1.32%

SAVA 0.81%

SAVAW 0.00%

SBBP 1.52%

SBTX 1.03%

SCNI 60.46%

SCPH -1.69%

SCPS 0.00%

SEEL -4.62%

SEER -3.37%

SELB -8.00%

SESN 7.29%

SGEN -0.07%

SGMO -17.30%

SGMT 1.93%

SGTX -2.56%

SIOX 22.63%

SLDB -5.44%

SLGL -2.22%

SLN -1.55%

SLNO 0.19%

SLRX 2.89%

SLS -16.67%

SMMT -5.84%

SNDX -1.14%

SNGX -5.91%

SNPX -3.97%

SONN -4.75%

SPPI -0.49%

SPRB 0.49%

SPRC -3.16%

SPRO -5.88%

SRNE 20.00%

SRPT -4.89%

SRRA 0.00%

SRRK -7.09%

SRZN -1.70%

STAB 0.00%

STOK -4.00%

STRO -7.51%

STSA 0.00%

STTK -19.55%

SURF -0.93%

SVRA -5.15%

SWTX -4.88%

SYBX -0.63%

SYRS -4.83%

TALS -0.73%

TARA -0.78%

TARS -6.91%

TBPH -0.59%

TCBP -8.64%

TCDA 0.00%

TCON 6.35%

TCRR 0.00%

TCRT 1.05%

TCRX -11.43%

TECH -1.40%

TENX -3.43%

TERN -2.93%

TFFP 0.52%

TGTX 0.12%

THRX 0.12%

TIL -2.06%

TLC 0.00%

TLSA 5.78%

TNGX 5.04%

TNXP -2.61%

TNYA -1.79%

TPST 0.34%

TRDA -3.61%

TRVI 2.08%

TRVN -1.88%

TSHA 1.51%

TSVT 3.29%

TTNP 1.45%

TVTX 2.23%

TYRA -8.69%

UBX -4.17%

UNCY 0.22%

URGN -4.79%

UTHR 3.12%

VACC 11.36%

VALN -1.55%

VAXX -0.11%

VBIV -3.61%

VBLT -8.77%

VCEL -1.37%

VCNX -3.70%

VCYT 1.96%

VERA -0.83%

VERU 2.29%

VERV -2.77%

VIGL -2.08%

VINC -4.90%

VIR -5.85%

VIRI 4.95%

VIRX -3.62%

VKTX 0.00%

VLON -13.04%

VNDA 1.76%

VOR 1.74%

VRCA 0.49%

VRDN -1.93%

VRNA 10.04%

VRPX 10.77%

VRTX -1.46%

VSTM 0.00%

VTGN -2.84%

VTVT -0.10%

VTYX -4.51%

VXRT -8.25%

VYGR -2.94%

VYNE 2.16%

VYNT 7.78%

WINT 7.98%

WVE -3.85%

XBIO 6.75%

XBIT -0.33%

XCUR -3.10%

XENE -1.75%

XERS -0.91%

XFOR -2.75%

XLO -6.86%

XLRN 0.00%

XNCR -5.15%

XOMA -4.31%

XOMAO 0.68%

XOMAP -0.14%

XRTX 1.96%

YMAB -1.34%

ZGNX 0.00%

ZIOP -0.88%

ZLAB 1.55%

ZNTL -5.09%

ZSAN 0.00%

Tūris Koreliacija

Ilgas: 0.31 (neutral)

Trumpas: 0.24 (neutral)

Signal:(68.183) Neutral

Gracell Biotechnologies Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Gracell Biotechnologies Koreliacija - Valiuta/Žaliavos

-0.71
( moderate negative )

-0.55
( weak negative )

0.59
( weak )

0.34
( neutral )

-0.26
( neutral )

0.73
( moderate )

Gracell Biotechnologies Finansinės ataskaitos

Annual	2022
Pajamos:	CNY0
Bruto pelnas:	CNY0 (0.00 %)
EPS:	CNY-5.65

FY	2022
Pajamos:	CNY0
Bruto pelnas:	CNY0 (0.00 %)
EPS:	CNY-5.65

FY	2021
Pajamos:	CNY366 000
Bruto pelnas:	CNY0.00 (0.00 %)
EPS:	CNY-4.31

FY	2020
Pajamos:	CNY0.00
Bruto pelnas:	CNY0.00 (0.00 %)
EPS:	CNY-13.85

Financial Reports:

No articles found.

Gracell Biotechnologies Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Gracell Biotechnologies

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.